South Korea Adalimumab Drugs Market Insight
Published: 30 May 2026 | Report Format: Electronic (PDF)
The South Korea adalimumab drugs market is expected to display strong growth in the coming years with a CAGR of 7.1%, due to an increase in the number of patients suffering from autoimmune diseases and increasing popularity of biological treatments and biosimilars in the field of rheumatology, gastroenterology, and immunology.
South Korea Adalimumab Drugs Market Insights Forecasts to 2035
- The South Korea Adalimumab Drugs Market Size Was Estimated USD 436.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.1% from 2025 to 2035
- The South Korea Adalimumab Drugs Market Size is Expected to rise around USD 867.2 Million by 2035
Notable Insights for the South Korea Adalimumab Drugs Market
- The Biosimilar Adalimumab segment is expected to represent around 63% of the South Korea Adalimumab Drugs Market share in 2025 due to an increase in the adoption of cost-effective treatment options from physicians.
- The Rheumatoid Arthritis segment will capture almost 34% market share in 2025 due to the high prevalence rate of chronic inflammatory diseases and increased demand for effective biologic treatments.
- The total revenue of AbbVie Inc., worldwide, in 2025 was more than USD 61 billion due to the demand for immunology treatments and biosimilars products.
- Increasing investments in biosimilar facilities, AI-based biological drugs, and injectable delivery systems contribute to the growth of the market, as next-generation adalimumab improves patient compliance by around 39% and reduces injection pain by almost 31%.
Download the eBook (ToC)
Why Buy This Report
- Provides comprehensive analysis of biologic therapeutics, biosimilar manufacturing technologies, and autoimmune disease treatment developments influencing growth in the South Korea Adalimumab Drugs Market.
- Offers strategic insights into emerging technologies including high-concentration citrate-free biologics, AI-powered pharmaceutical manufacturing systems, digital biologics monitoring platforms, and advanced self-administration drug delivery devices.
- Supports stakeholders in evaluating competitive positioning, biologics investment strategies, biosimilar commercialization developments, and immunology therapeutic innovation trends across South Korea.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea Adalimumab Drugs Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Adalimumab Drugs Market
- AbbVie Inc.
- Celltrion Inc.
- Samsung Bioepis Co., Ltd.
- Amgen Inc.
- Pfizer Inc.
- Sandoz Group AG
- Biocon Biologics Ltd.
- Fresenius Kabi AG
- Organon & Co.
- Boehringer Ingelheim International GmbH
Recent Developments:
- In April 2025, Celltrion announced that the U.S. FDA granted interchangeability designation for YUFLYMA (adalimumab-aaty), strengthening the company’s global biosimilar commercialization strategy for autoimmune disease therapeutics.
- In May 2025, Celltrion received expanded interchangeability designation for all marketed dosage forms and strengths of YUFLYMA, including autoinjectors and prefilled syringes.
Market Segmentation:
South Korea Adalimumab Drugs Market, By Product Type
- Originator Biologics
- Biosimilar Adalimumab
- High-Concentration Citrate-Free Formulations
- Self-Injectable Autoinjector Therapies
South Korea Adalimumab Drugs Market, By Technology
- AI-Based Biologics Manufacturing Systems
- Advanced Injectable Drug Delivery Platforms
- Biosimilar Development Technologies
- Digital Therapeutic Monitoring Systems
South Korea Adalimumab Drugs Market, By Application
- Rheumatoid Arthritis
- Crohn’s Disease
- Ulcerative Colitis
- Psoriasis
- Ankylosing Spondylitis
Expert Views:
The market for South Korean adalimumab biological agents is predicted to experience sustainable growth due to increased prevalence of autoimmune conditions, growing biosimilars adoption rate, and enhanced investments in biologic production facilities. Adoption of high concentration formulations without citrate, pharmaceutical manufacturing aided by artificial intelligence, digital health monitoring solutions, and self-administration mechanisms in the field of biologics is likely to enhance drug availability and drive future demand within the domains of rheumatology, gastroenterology, dermatology, and immunology.
Author: Aditi and Govind By Spherical Insights and Consulting